Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Release
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Release
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Evaluating Drugs to Improve Vision In Diabetic Macular Edema
Clinical Breakthroughs

Evaluating Drugs to Improve Vision In Diabetic Macular Edema

By Marla PaulFeb 19, 2015
Share
Facebook Twitter Email
Lee Jampol, MD, Louis Feinberg, MD, Professor of Ophthalmology, chairs the Diabetic Retinopathy Clinical Research Network, which produced the paper demonstrating the drug Eylea is superior to other options for improving the eyesight of persons with poor vision due to diabetic macular edema.

A national study led by Northwestern Medicine shows the drug Eylea is superior for improving the eyesight of persons with poor vision due to diabetic macular edema, a major cause of vision loss from diabetes, according to Lee Jampol, MD, Louis Feinberg, MD, Professor of Ophthalmology. Dr. Jampol chairs the Diabetic Retinopathy Clinical Research Network, which produced the paper published in the New England Journal of Medicine.

For individuals with only mild vision impairment (20/40 to 20/32), all three existing drugs to treat diabetic macular edema – Eylea, Lucentis and Avastin – performed similarly. Eylea was more effective for patients with 20/50 or worse vision.

“This condition is an increasingly common public health problem due to the increasing prevalence of obesity and resulting diabetes,” Dr. Jampol said. “The study will help doctors and patients make informed decisions about which drug to choose for treatment.”

Diabetic macular edema is the major cause of diabetes-related vision loss. It can occur in people with diabetic retinopathy, an eye disease associated with abnormal blood vessels in the retina. Diabetes damages blood vessels in the eye, causing them to leak and the retina to swell. The condition distorts vision and can result in blindness. An estimated 7.7 million people in the U.S. have diabetic retinopathy, and 750,000 of them have diabetic macular edema.

In the study, the group with initial poor vision (20/50 or worse at the start of the trial) that took Eylea improved on the average about 18 letters on the eye chart, almost four lines. The group taking Lucentis improved on average almost three lines, and those on Avastin improved on average almost 2.5 lines.

All three drugs target a substance called VEGF, vascular endothelial growth factor, which causes the blood vessels to leak. The drugs work by binding to VEGF or blocking its action, thereby reducing swelling.

In addition, a smaller percentage of patients on Eylea (36 percent) required laser treatment for persistent edema that did not resolve with the anti-VEGF treatment alone, compared to those on Avastin (56 percent) or Lucentis (46 percent.)

The trial enrolled 660 participants with diabetic macular edema at 88 clinical trial sites across the U.S. When the study began, participants were an average of 61 years old and had type 1 or type 2 diabetes for an average of 17 years.

The study was funded by grants EY14231, EY14229 and EY18817 from the National Eye Institute of the National Institutes of Health.

If you are interested in participating in research at Northwestern University, please call the NU Study line at 1-855-NU-STUDY. Or get connected by visiting https://registar-prod.nubic.northwestern.edu to sign up for Northwestern’s Research Registry.

Ophthalmology Pharmacology Research
Share. Facebook Twitter Email

Related Posts

Humans are Not Just Big Mice: Identifying Science’s Muscle-Scaling Problem

Mar 20, 2023

Predicting Risk of Blood Clots in Brain Tumors

Mar 16, 2023

Understanding How Exercise Induces Systemic Metabolic Benefits

Mar 15, 2023

Comments are closed.

Latest News

Humans are Not Just Big Mice: Identifying Science’s Muscle-Scaling Problem

Mar 20, 2023

AOA Honors New Members

Mar 20, 2023

Celebrating Feinberg’s 2023 Match Day

Mar 17, 2023

Predicting Risk of Blood Clots in Brain Tumors

Mar 16, 2023

Understanding How Exercise Induces Systemic Metabolic Benefits

Mar 15, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
_5NM1245
230204_SERIO_MANDELL_Feinberg_Formal_0928
_5NM1715
_5NM0526
_5NM1026 (1)
_5NM1906
_5NM2173
230204_SERIO_MANDELL_Feinberg_Formal_0896
230204_SERIO_MANDELL_Feinberg_Formal_1113
230204_SERIO_MANDELL_Feinberg_Formal_1868
230204_SERIO_MANDELL_Feinberg_Formal_1237
230204_SERIO_MANDELL_Feinberg_Formal_1172

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.